semaglutide alzheimer's trial evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of in early-stage symptomatic disease | Alzheimer's Research & Therapy Alzheimer's trial exposes GLP-1 limits

This means it hasn't undergone the rigorous testing required to ensure its safety and efficacy

The Hunter Williams Podcast By Hunter Williams The Hunter Williams Podcast goes where mainstream medicine won't deep into the science of peptides, hormone optimization, metabolic health, and biohacking protocols that actually move the needle

By week 9, patients typically move to 1.0 mg weekly, and by week 13, they reach 2.0 mgthe standard maintenance dose used in most weight loss studies

with 1,025 protein targets significant under FDR control)

Adjustment Criteria: Decisions on treatment changes depend on the initial deficiency level, neurological symptoms, and how well the patient responds

2025;5(5):oeaf117